GenSight Biologics SA's total assets for Q4 2025 were €8.26M, an increase of 12.31% from the previous quarter. DE:G49N total liabilities were €33.20M for the fiscal quarter, a -15.86% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.